KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Capital Expenditures (2016 - 2025)

Globus Medical (GMED) has disclosed Capital Expenditures for 15 consecutive years, with -$105.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 17.96% year-over-year to -$105.0 million, compared with a TTM value of $13.5 million through Dec 2025, up 44.96%, and an annual FY2025 reading of $13.5 million, up 44.96% over the prior year.
  • Capital Expenditures was -$105.0 million for Q4 2025 at Globus Medical, down from $105.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $105.0 million in Q3 2025 and bottomed at -$105.0 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $8.0 million, with a median of $3.8 million recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 6834.21% in 2024, while the deepest fall reached 7986.36% in 2024.
  • Year by year, Capital Expenditures stood at $53.4 million in 2021, then grew by 28.65% to $68.7 million in 2022, then tumbled by 98.36% to $1.1 million in 2023, then plummeted by 7986.36% to -$89.0 million in 2024, then dropped by 17.96% to -$105.0 million in 2025.
  • Business Quant data shows Capital Expenditures for GMED at -$105.0 million in Q4 2025, $105.0 million in Q3 2025, and $3.4 million in Q2 2025.